What is the official ID of this bill?

The official print number for this legislation is HR 4531.

When did the legislative process begin?

The process officially started on 2023-07-11.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr4531/BILLS-118hr4531rfs.htm

Where is the official voting record?

The official roll call vote is recorded at: https://clerk.house.gov/evs/2023/roll715.xml

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Guthrie, Brett [R-KY-2].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 386 - 37 (Roll no. 715). (text: 12/11/2023 CR H6790-6794)

Analysis and Potential Impact of HR 4531

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Reauthorizing Opioid Programs, Expanding Medicaid Access, and Combating Xylazine

Q: What are the main provisions?

Key points include: Increased funding for opioid prevention and treatment programs, including for first responders and community support. Expanded Medicaid coverage for substance use disorder and mental health treatment, including for pregnant women and foster youth. Classification of xylazine, a substance often mixed with illicit drugs, as a controlled substance to combat its illegal trafficking. Requirement to update guidelines for opioid overdose reversal agents to include all approved medications.

This act extends and expands programs supporting opioid use disorder prevention, treatment, and recovery. It increases funding for key services, improves access to care for pregnant women and youth, and modifies Medicaid to facilitate healthcare access for individuals with mental health conditions and substance use disorders.

Key points

Increased funding for opioid prevention and treatment programs, including for first responders and community support.

Expanded Medicaid coverage for substance use disorder and mental health treatment, including for pregnant women and foster youth.

Classification of xylazine, a substance often mixed with illicit drugs, as a controlled substance to combat its illegal trafficking.

Requirement to update guidelines for opioid overdose reversal agents to include all approved medications.

article Official text account_balance Process page notifications_active Track this Bill

91%

VOTING RESULTS

2023-12-12

For 386

Against 37

Abstain 0

Full voting results open_in_new

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Support for Patients and Communities Reauthorization Act

Print number: HR 4531

Sponsor: Rep. Guthrie, Brett [R-KY-2]

Process start date: 2023-07-11

Voting date: 2023-12-12

Meeting no: 1

Voting no: 715

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch